Search Result

Results for "

metabolite，liver

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Cytotoxin (2) Apoptosis (1) Bacterial (1) COX (2) Cytochrome P450 (3) DNA/RNA Synthesis (1) Drug Metabolite (16) Drug-Linker Conjugates for ADC (3) EGFR (1) Endogenous Metabolite (22) Fluorescent Dye (1) Fungal (1) IGF-1R (1) Influenza Virus (4) Isotope-Labeled Compounds (9) LXR (1) Microtubule/Tubulin (1) Na+/K+ ATPase (1) Necroptosis (1) NO Synthase (2) Parasite (5) PKC (1)
By Research Areas:	Cancer (16) Cardiovascular Disease (7) Endocrinology (2) Infection (9) Inflammation/Immunology (14) Metabolic Disease (18) Neurological Disease (2)
Click Chemistry:	DBCO (1)

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Peptides

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-126967A

1-Palmitoyl-sn-glycerol 3-phosphate 1-P-GPA	Others	Metabolic Disease
1-Palmitoyl-sn-glycerol 3-phosphate (1-P-GPA) is an endogenous metabolite. 1-Palmitoyl-sn-glycerol 3-phosphate can be used for the research of non‐alcoholic fatty liver disease .

HY-121385

Hydroxy bosentan Ro 48-5033	Endogenous Metabolite	Cardiovascular Disease
Hydroxy bosentan (Ro 48-5033) is a primary metabolite of Bosentan (BOS) metabolized by the cytochrome P450 system in the liver. Ro 48-5033 assists BOS pharmacologically, retaining 10%-20% activities .

HY-118167

Monoethylglycinexylidide	Drug Metabolite	Metabolic Disease Inflammation/Immunology
Monoethylglycinexylidide is a *metabolite* of Lidocain (HY-B0185) via oxidative N-deethylation of Lignocaine by liver cytochrome P-450 enzymes in the liver ^{[1] ^.}

HY-155792

Troglitazone glucuronide

Others Others

Troglitazone glucuronide (Compound M2) is an initial metabolite of troglitazone in the liver .
HY-N7390

Cholesterol glucuronide

Endogenous Metabolite Metabolic Disease

Cholesterol glucuronide is an endogenous metabolite of lipid generated in the liver by UDP glucuonyltransferase .

Troglitazone glucuronide	Others	Others
Troglitazone glucuronide (Compound M2) is an initial metabolite of troglitazone in the liver .

Cholesterol glucuronide	Endogenous Metabolite	Metabolic Disease
Cholesterol glucuronide is an endogenous metabolite of lipid generated in the liver by UDP glucuonyltransferase .

HY-W099331

Monoethylglycinexylidide hydrochloride MEGX hydrochloride; Norlidocaine hydrochloride	Drug Metabolite	Metabolic Disease Inflammation/Immunology
Monoethylglycinexylidide (MEGX) hydrochloride is a *metabolite* of Lidocain (HY-B0185) via oxidative N-deethylation of Lignocaine by liver cytochrome P-450 enzymes in the liver. Monoethylglycinexylidide has proven to be a highly sensitive indicator of hepatic dysfunction, especially in the field of liver transplantation .

HY-133797

Cyclobenzaprine N-oxide	Drug Metabolite	Neurological Disease
Cyclobenzaprine N-oxide is the tertiary amine metabolite of Cyclobenzaprine (HY-B0740) in liver particles. Cyclobenzaprine is a skeletal muscle relaxant and is active on the central nervous system. The liver cytosol from liver particles has reductase activity that can reduce Cyclobenzaprine N-oxide to the corresponding amine .

HY-Y0801

2,6-Dihydroxybenzoic acid

2,6-Dihydroxybenzoic acid is a secondary metabolite of salicylic acid which has been hydrolyzed by liver enzymes during phase I metabolism.

2,6-Dihydroxybenzoic acid
2,6-Dihydroxybenzoic acid is a secondary metabolite of salicylic acid which has been hydrolyzed by liver enzymes during phase I metabolism.

HY-113318

Coproporphyrin I	Endogenous Metabolite	Metabolic Disease
Coproporphyrin I is an endogenous metabolite present in Urine and Blood that can be used for the research of Liver Disease and Porphyria .

HY-125934

Allocholic acid	Others	Cancer
Allocholic acid is a typically fetal bile acid found in vertebrates and reappears during liver regeneration and carcinogenesis, besides it is also a conjugate acid of allocholate and an isomer of cholic acid. Allocholic acid is a potent and specific stimulant of the adult olfactory system, it has a role as a marine metabolite, a rat metabolite and a human metabolite .

HY-40161

Indole-3-carboxylic acid	Endogenous Metabolite	Metabolic Disease
Indole-3-carboxylic acid is a normal urinary indolic tryptophan metabolite and has been found elevated in patients with liver diseases .

HY-111431

p-Cresyl sulfate 1 Publications Verification p-Tolyl sulfate	Endogenous Metabolite	Metabolic Disease
p-Cresyl Sulfate, a major uremic toxin derived from the metabolites of tyrosine and phenylalanine through liver, existed in the blood of patients with chronic kidney disease (CKD).

HY-N10207

Penicitide A	Endogenous Metabolite	Infection Cancer
Penicitide A is a marine secondary metabolite. Penicitide A shows moderate cytotoxicity against pathogen A. brassicae and the human hepatocellular liver carcinoma (HepG2) cell line .

HY-W403633

Hexahydrohippuric acid	Bacterial	Infection
Hexahydrohippuric acid is a metabolite of Shikimate acid in both liver and kidney, under microbial metabolism effect. Hexahydrohippuric acid is made of cyclohexane carboxylic acid and glycinamide, and shows antibacterial activity .

HY-133610

3,4,6-Trichlorocatechol	Others	Others
3,4,6-trichlorocatechol (TCC) is the metabolite produced by industrial pollutant through post-mitochondrial liver fraction from Aroclor-1254 induced rats .

HY-B1069

Molsidomine SIN-10; Morsydomine	Drug Metabolite	Cardiovascular Disease
Molsidomine is an orally active, long acting vasodilating drug, metabolized in the liver to the active metabolite linsidomine, which is an unstable compound that releases nitric oxide (NO) upon decay as the actual vasodilating compound.

HY-119536

Norsufentanil	Others	Neurological Disease
Sufentanil is a potent synthetic opioid analgesic. Norsufentanil, a metabolite of sufentanil, is produced by the oxidative N-dealkylation of the liver cytochrome P450 isomer. Norsufentanil has analgesic activity .

HY-N8549A

5-Dihydrocortisone	Endogenous Metabolite	Metabolic Disease
5-Dihydrocortisone is a 5-Dihydrocortisone with mixture of isomers. 5β-Dihydrocortisone is a sterol metabolite of cortisone by 5β-reductase (AKR1D1) in liver

HY-B0794S

AZ7550-d5	EGFR IGF-1R Drug Metabolite	Others
AZ7550-d₅ is the deuterium labeled AZ7550 (HY-B0794). AZ7550, an active metabolite of Osimtinib (AZD9291; HY-15772), inhibits the activity of IGF1R with an IC50 of 1.6 μM[1][2].

HY-126665

DMEA-PNU-159682	ADC Cytotoxin	Cancer
DMEA-PNU-159682 (molecule D12) is a ADC cytotoxin molecule including metabolites of nemorubicin (MMDX) from liver microsomes and a potent ADCs cytotoxin PNU-159682 .

HY-126665A

DMEA-PNU-159682 dichloroacetate	ADC Cytotoxin	Cancer
DMEA-PNU-159682 (molecule D12) dichloroacetate is an ADC cytotoxin molecule including metabolites of nemorubicin (MMDX) from liver microsomes and a potent ADCs cytotoxin PNU-159682 .

HY-W009934

2-Phenyl-2-(2-pyridyl)acetonitrile α-Phenyl-2-pyridineacetonitrile	Drug Metabolite	Endocrinology
2-Phenyl-2-(2-pyridyl)acetonitrile is the major metabolite of SC 15396 metabolized by the supernatant fraction of rat liver homogenate. SC 15396 is an antigastrin that inhibits gastric secretion .

HY-B1069R

Molsidomine (Standard) SIN-10 (Standard); Morsydomine (Standard)	Drug Metabolite	Cardiovascular Disease
Molsidomine (Standard) is the analytical standard of Molsidomine. This product is intended for research and analytical applications. Molsidomine is an orally available, long-acting vasodilator that is metabolized in the liver to the active metabolite Linsidomine, an unstable compound that releases NO and acts as a vasodilator.

HY-W016099

3-Methyl-2-quinoxalinecarboxylic acid MQCA	Drug Metabolite	Cancer
3-Methyl-2-quinoxalinecarboxylic acid (MQCA), an important N-oxide reductive metabolite of Quinocetone or Olaquindox, potently inhibits the growth of Chang liver cells through S phase arrest of the cell cycle .

HY-127166

Colchiceine O10-Demethylcolchicine	Microtubule/Tubulin	Inflammation/Immunology
Colchiceine is one of several metabolites of the anti-gout medication Colchicine (HY-16569). Colchicine is a tubulin inhibitor and a microtubule disrupting agent, and may protect rats from developing liver injury and fibrosis .

HY-W003371

CGP 44 645	Drug Metabolite	Others
CGP 44 645 is the methanol metabolite of Letrozole (HY-14248) and is a molecular indicator for evaluating its metabolic kinetics in microsomes in vitro. Levels of CGP 44 645 in rat liver microsomes may be sex-specific .

HY-B1984

p,p'-DDD 4,4'-DDD; p,p'-Dichlorodiphenyl dichloroethane
p,p'-DDD is a major metabolite of p,p'-DDT. p,p'-DDD occurs in the feces and livers of rats, that are given p,p'-DDT by stomach tube, but not of rats injected intraperitoneally with p,p'-DDT .

HY-W337335

1-Palmitoyl-sn-glycerol 3-phosphate sodium salt 1-P-GPA sodium salt	Endogenous Metabolite	Metabolic Disease
1-Palmitoyl-sn-glycerol 3-phosphate (sodium salt) (1-P-GPA (sodium salt)) is an endogenous metabolite. 1-Palmitoyl-sn-glycerol 3-phosphate (sodium salt) can be used in the study of non-alcoholic fatty liver disease .

HY-32349S

Ercalcidiol-d3 25-Hydroxy Vitamin D2-d₃	Endogenous Metabolite	Metabolic Disease
Ercalcidiol-d₃ is the deuterium labeled Ercalcidiol. Ercalcidiol is a metabolite of Vitamins D2. Ercalcidiol can be used as an indicator of vitamins D status .

HY-N11676

6-Hydroxy-TSU-68	Drug Metabolite	Cancer
6-Hydroxy-TSU-68 is a derivative of TSU-68 (HY-10517). It is a metabolite of the biotransformation pathway of TSU-68 in human liver microsomes. The content represents the self-induced hydroxylation level of TSU-68 .

HY-N11677

7-Hydroxy-TSU-68	Drug Metabolite	Others
7-Hydroxy-TSU-68 is a derivative of TSU-68 (HY-10517). It is a metabolite of the biotransformation pathway of TSU-68 in human liver microsomes. The content represents the self-induced hydroxylation level of TSU-68 .

HY-116444A

16-HETE	Na+/K+ ATPase	Cardiovascular Disease Inflammation/Immunology
16-HETE is arachidonic acid metabolite through subterminal hydroxylation by cytochrome P-450. 16-HETE exhibits vasodilatory and PMN inhibitory effects and serves as biomarker for early stages of non-alcoholic fatty liver disease .

HY-100644

Trimethoprim N-oxide Trimethoprim 1-N-oxide
Trimethoprim N-oxide (Trimethoprim 1-N-oxide) belongs to human urinary metabolites. Trimethoprim N-oxide is generated by oxidation of nitrogen atoms in the pyrimidine ring. Trimethoprim N-oxide is formed predominantly by CYP1A2 in human liver microsomes .

HY-120607

Chevalone C	Parasite	Infection Cancer
Chevalone C, a meroterpenoid fungal metabolite, shows antimalarial activity with IC₅₀ value of 25.00 μg/mL. Chevalone C has anti-proliferative activity on colon HCT116, liver HepG2 and melanoma A375 cancer cell lines .

HY-139576

Larsucosterol DUR-928	Endogenous Metabolite	Metabolic Disease
Larsucosterol (DUR-928), a cholesterol metabolite, is a potent liver X receptor (LXR) antagonist. Larsucosterol as a potent endogenous regulator decreases lipogenesis. Larsucosterol inhibits the cholesterol biosynthesis via decreasing mRNA levels and inhibiting the activation of SREBP-1 .

HY-139576A

Larsucosterol sodium DUR-928 sodium	Endogenous Metabolite	Metabolic Disease
Larsucosterol (DUR-928) sodium, a cholesterol metabolite, is a potent liver X receptor (LXR) antagonist. Larsucosterol sodium as a potent endogenous regulator decreases lipogenesis. Larsucosterol sodium inhibits the cholesterol biosynthesis via decreasing mRNA levels and inhibiting the activation of SREBP-1 .

HY-113018A

(S)-Ibuprofen acyl-β-D-glucuronide (S)-Ibuprofen glucuronide	Others	Inflammation/Immunology
(S)-Ibuprofen acyl-β-D-glucuronide ((S)-Ibuprofen glucuronide) is a compound used to study the metabolism and pharmacokinetics of S-ibuprofen, a non-steroidal anti-inflammatory drug. (S)-Ibuprofen acyl-β-D-glucuronide is an acylglucuronic acid metabolite produced by S-ibuprofen in the liver .

HY-W050031

(S)-3-Hydroxybutanoic acid 1 Publications Verification (S)-β-Hydroxybutanoic acid; L-(+)-3-Hydroxybutyric acid; L-β-Hydroxybutyric acid	Endogenous Metabolite	Others
(S)-3-Hydroxybutanoic acid is a normal human metabolite, that has been found elevated in geriatric patients remitting from depression. In humans, 3-Hydroxybutyric acid is synthesized in the liver from acetyl-CoA, and can be used as an energy source by the brain when blood glucose is low.

HY-W017464

NAPQI	Drug Metabolite Endogenous Metabolite	Metabolic Disease
NAPQI is the toxic metabolite of Acetaminophen (HY-66005). NAPQI is also an inhibitor of enzymes in the vitamin K cycle. NAPQI is rapidly detoxified by glutathione (GSH), but in situations of GSH deficiency, excess NAPQI reacts with cysteine residues in proteins, causing cell death and toxicity in the liver .

HY-129491S

O-Desmethyl Midostaurin-d5 CGP62221-d₅; O-Desmethyl PKC412-d₅	Isotope-Labeled Compounds Drug Metabolite	Cancer
O-Desmethyl Midostaurin-d₅ is a deuterium labeled O-Desmethyl PKC412. O-Desmethyl Midostaurin (CGP62221; O-Desmethyl PKC412) is the active metabolite of Midostaurin (HY-10230) via cytochrome P450 liver enzyme metabolism[1].

HY-121385S

Hydroxy Bosentan-d6 Ro 48-5033-d₆	Isotope-Labeled Compounds Endogenous Metabolite	Cardiovascular Disease
Hydroxy Bosentan-d₆ is deuterium labeled Hydroxy bosentan. Hydroxy bosentan (Ro 48-5033) is a primary metabolite of Bosentan (BOS) metabolized by the cytochrome P450 system in the liver. Ro 48-5033 assists BOS pharmacologically, retaining 10%-20% activities[1].

HY-121385S1

Hydroxy Bosentan-d4 Ro 48-5033-d₄	Isotope-Labeled Compounds Endogenous Metabolite	Cardiovascular Disease
Hydroxy Bosentan-d₄ is deuterium labeled Hydroxy bosentan. Hydroxy bosentan (Ro 48-5033) is a primary metabolite of Bosentan (BOS) metabolized by the cytochrome P450 system in the liver. Ro 48-5033 assists BOS pharmacologically, retaining 10%-20% activities[1].

HY-Y0698

Thioacetamide Acetothioamide; TAA; Thiacetamide	Necroptosis	Inflammation/Immunology
Thioacetamide (TAA) is an indirect hepatotoxin and causes parenchymal cell necrosis. Thioacetamide requires metabolic activation by microsomal CYP2E1 to thioacetamide-S-oxide initially and then to thioacetamide-S-dioxide, which is a highly reactive metabolite, and its reactive metabolites covalently bind to proteins and lipids thereby causing oxidative stress and centrilobular necrosis. Thioacetamide can induce chronic liver fibrosis, encephalopathy and other events model .

HY-W018392

Mono-(2-ethylhexyl) phthalate Maximum Cited Publications 6 Publications Verification MEHP; Phthalic acid mono-2-ethylhexyl ester	Endogenous Metabolite	Metabolic Disease
Mono-(2-ethylhexyl) phthalate (MEHP) is a major bioactive metabolite of diethylhexyl phthalate (DEHP). Mono-(2-ethylhexyl) phthalate can promote fatty acid synthesis in hepatocytes by regulating the expression of relevant genes and proteins, contributing to non-alcoholic fatty liver disease (NAFLD) .

HY-139576B

Larsucosterol (trimethylamine) DUR-928 (trimethylamine)	LXR Endogenous Metabolite	Metabolic Disease
Larsucosterol (DUR-928) trimethylamine, a cholesterol metabolite, is a potent liver X receptor (LXR) antagonist. Larsucosterol trimethylamine as a potent endogenous regulator decreases lipogenesis. Larsucosterol trimethylamine inhibits the cholesterol biosynthesis via decreasing mRNA levels and inhibiting the activation of SREBP-1 .

HY-148642

12-Hydroxynevirapine 12-hydroxy-NVP; 12-OH-NVP	Drug Metabolite	Infection
12-Hydroxynevirapine (12-hydroxy-NVP; 12-OH-NVP) is a major oxidative metabolite of Nevirapine (HY-10570). Nevirapine is a non-nucleoside reverse transcriptase inhibitor indicated for the HIV-1 infections. Nevirapine causes idiosyncratic hepatotoxicity and mild-to-severe skin rashes. 12-Hydroxynevirapine, a non-reactive metabolite, can be bioactivated by sulphotransferases (SULTs) in the liver and skin, yielding the reactive species 12-Sulphoxy-nevirapine .

HY-113381

2-Hydroxybutyric acid α-Hydroxybutyric acid	Endogenous Metabolite	Metabolic Disease Inflammation/Immunology
2-Hydroxybutyric acid (α-Hydroxybutyric acid ) is converted from 2-Aminobutyric acid, with 2-oxobutyric acid as an intermediate metabolite . 2-Hydroxybutyric acid is a potential biomarker for type 2 diabetes and preeclampsia . 2-Hydroxybutyric acid prevents the acetaminophen (AP)-induced liver injury .

HY-W040705

2-(Methylamino)benzoic acid N-Methylanthranilic acid	Drug Metabolite	Others
2-(Methylamino)benzoic acid is the main metabolite of methyl-N-methylanthranilates (MMA) (HY-76705) and is the compound in which the ester group is converted. MMA can be isolated from citrus fruits and has potential analgesic activity. 2-(Methylamino)benzoic acid was used to detect the metabolic levels of MMA in rat liver .

HY-113111

11,12-DiHETrE	Endogenous Metabolite	Inflammation/Immunology
11,12-DiHETrE, an endogenous metabolite, is a Cytochrome P450 (P450) eicosanoid. 11,12-DiHETrE can be used for preterm labor research. 11,12-DiHETrE can be used as a single biomarker for differentiating NAFL (nonalcoholic fatty liver) from NASH (nonalcoholic steatohepatitis) .

HY-B1984S

p,p'-DDD-d8 4,4'-DDD-d₈; p,p'-Dichlorodiphenyl dichloroethane-d₈	Drug Metabolite	Others
p,p'-DDD-d₈ is the deuterium labeled p,p'-DDD[1]. p,p'-DDD is a major metabolite of p,p'-DDT. p,p'-DDD occurs in the feces and livers of rats, that are given p,p'-DDT by stomach tube, but not of rats injected intraperitoneally with p,p'-DDT[2][3].

Cat. No.	Product Name

HY-L076

Drug-Induced Liver Injury (DILI) Compound Library

1392 compounds

Drug-induced liver injury (DILI; also known as drug-induced hepatotoxicity) is caused by medications (prescription or OTC), herbal and dietary supplements (HDS), or other xenobiotics that result in abnormalities in liver tests or in hepatic dysfunction that cannot be explained by other causes. Drugs are an important cause of liver injury. Drug-induced hepatic injury is the most common reason cited for withdrawal of an approved drug.

DILI is thought to occur via several different mechanisms. Among these are direct impairment of the structural (e.g., mitochondrial dysfunction) and functional integrity of the liver; production of a metabolite that alters hepatocellular structure and function; production of a reactive drug metabolite that binds to hepatic proteins to produce new antigenic drug-protein adducts, which are targeted by hosts’ defenses (the hapten hypothesis); and initiation of a systemic hypersensitivity response (i.e., drug allergy) that damages the liver.

MCE Drug-induced Liver Injury (DILI) Compound Library contains a unique collection of 1392 hepatotoxicity causing compounds and is a powerful tool to research DILI and other drug toxicities. This library can be used to understand the mechanisms of DILI, identify biomarkers for early DILI prediction, and allow timely recognition during drug development, thus finally achieving successful DILI prevention and assessment in the pre-marketing phase.

HY-L148

TCA Cycle Compound Library

65 compounds

The TCA cycle (tricarboxylic acid cycle)—is also known as the Krebs cycle or the citric acid cycle (CAC). The TCA cycle is a series of chemical reactions that release stored energy through the oxidation of acetyl-CoA in carbohydrates, fats, and proteins.

For decades, the TCA cycle has been considered as the central pathway for cell oxidative phosphorylation to produce energy and biosynthesis. Research shows that TCA cycle is associated with many diseases, especially cancer. In colon carcinoma, liver cancer and other cancers, there are mutations that lead to the imbalance of TCA cycle metabolites, indicating that TCA cycle may be related to the occurrence of cancer. Understanding the role and molecular mechanism of TCA cycle in inhibiting or promoting cancer progression will promote the development of new metabolite-based cancer treatment methods in the future.

MCE supplies a unique collection of 65 compounds related to the TCA cycle. MCE TCA Cycle Compound Library is a useful tool for the TCA cycle related research and anti-cancer drug development.

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-125934

Allocholic acid	Structural Classification Microorganisms Classification of Application Fields Animals Source classification Disease Research Fields Steroids Cancer	Others
Allocholic acid is a typically fetal bile acid found in vertebrates and reappears during liver regeneration and carcinogenesis, besides it is also a conjugate acid of allocholate and an isomer of cholic acid. Allocholic acid is a potent and specific stimulant of the adult olfactory system, it has a role as a marine metabolite, a rat metabolite and a human metabolite .

HY-126967A

1-Palmitoyl-sn-glycerol 3-phosphate 1-P-GPA	Structural Classification Natural Products Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Others
1-Palmitoyl-sn-glycerol 3-phosphate (1-P-GPA) is an endogenous metabolite. 1-Palmitoyl-sn-glycerol 3-phosphate can be used for the research of non‐alcoholic fatty liver disease .

HY-121385

Hydroxy bosentan Ro 48-5033	Cardiovascular Disease Structural Classification Natural Products Classification of Application Fields Source classification Endogenous metabolite Disease Research Fields	Endogenous Metabolite
Hydroxy bosentan (Ro 48-5033) is a primary metabolite of Bosentan (BOS) metabolized by the cytochrome P450 system in the liver. Ro 48-5033 assists BOS pharmacologically, retaining 10%-20% activities .

HY-N7390

Cholesterol glucuronide	Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields Steroids	Endogenous Metabolite
Cholesterol glucuronide is an endogenous metabolite of lipid generated in the liver by UDP glucuonyltransferase .

HY-113318

Coproporphyrin I	Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite
Coproporphyrin I is an endogenous metabolite present in Urine and Blood that can be used for the research of Liver Disease and Porphyria .

HY-40161

Indole-3-carboxylic acid	Alkaloids Human Gut Microbiota Metabolites Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields Indole Alkaloids	Endogenous Metabolite
Indole-3-carboxylic acid is a normal urinary indolic tryptophan metabolite and has been found elevated in patients with liver diseases .

HY-111431

p-Cresyl sulfate 1 Publications Verification p-Tolyl sulfate	Structural Classification Natural Products Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite
p-Cresyl Sulfate, a major uremic toxin derived from the metabolites of tyrosine and phenylalanine through liver, existed in the blood of patients with chronic kidney disease (CKD).

HY-N10207

Penicitide A	Infection Natural Products Microorganisms Classification of Application Fields Source classification Marine natural products Disease Research Fields Marine microorganism	Endogenous Metabolite
Penicitide A is a marine secondary metabolite. Penicitide A shows moderate cytotoxicity against pathogen A. brassicae and the human hepatocellular liver carcinoma (HepG2) cell line .

HY-N8549A

5-Dihydrocortisone	Structural Classification Classification of Application Fields Cardiacglycosides Source classification Metabolic Disease Endogenous metabolite Disease Research Fields Steroids	Endogenous Metabolite
5-Dihydrocortisone is a 5-Dihydrocortisone with mixture of isomers. 5β-Dihydrocortisone is a sterol metabolite of cortisone by 5β-reductase (AKR1D1) in liver

HY-127166

Colchiceine O10-Demethylcolchicine	Colchicaceae Structural Classification Alkaloids Other Alkaloids Source classification Plants Colchicum autumnale L.	Microtubule/Tubulin
Colchiceine is one of several metabolites of the anti-gout medication Colchicine (HY-16569). Colchicine is a tubulin inhibitor and a microtubule disrupting agent, and may protect rats from developing liver injury and fibrosis .

HY-W337335

1-Palmitoyl-sn-glycerol 3-phosphate sodium salt 1-P-GPA sodium salt	Structural Classification Natural Products Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite
1-Palmitoyl-sn-glycerol 3-phosphate (sodium salt) (1-P-GPA (sodium salt)) is an endogenous metabolite. 1-Palmitoyl-sn-glycerol 3-phosphate (sodium salt) can be used in the study of non-alcoholic fatty liver disease .

HY-N11676

6-Hydroxy-TSU-68	Structural Classification Alkaloids Monophenols Pyrrole Alkaloids Source classification Phenols Endogenous metabolite	Drug Metabolite
6-Hydroxy-TSU-68 is a derivative of TSU-68 (HY-10517). It is a metabolite of the biotransformation pathway of TSU-68 in human liver microsomes. The content represents the self-induced hydroxylation level of TSU-68 .

HY-N11677

7-Hydroxy-TSU-68	Structural Classification Alkaloids Monophenols Pyrrole Alkaloids Source classification Phenols Endogenous metabolite	Drug Metabolite
7-Hydroxy-TSU-68 is a derivative of TSU-68 (HY-10517). It is a metabolite of the biotransformation pathway of TSU-68 in human liver microsomes. The content represents the self-induced hydroxylation level of TSU-68 .

HY-120607

Chevalone C	Infection Triterpenes Microorganisms Classification of Application Fields Terpenoids Source classification Disease Research Fields	Parasite
Chevalone C, a meroterpenoid fungal metabolite, shows antimalarial activity with IC₅₀ value of 25.00 μg/mL. Chevalone C has anti-proliferative activity on colon HCT116, liver HepG2 and melanoma A375 cancer cell lines .

HY-139576

Larsucosterol DUR-928	Structural Classification Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields Steroids	Endogenous Metabolite
Larsucosterol (DUR-928), a cholesterol metabolite, is a potent liver X receptor (LXR) antagonist. Larsucosterol as a potent endogenous regulator decreases lipogenesis. Larsucosterol inhibits the cholesterol biosynthesis via decreasing mRNA levels and inhibiting the activation of SREBP-1 .

HY-139576A

Larsucosterol sodium DUR-928 sodium	Structural Classification Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields Steroids	Endogenous Metabolite
Larsucosterol (DUR-928) sodium, a cholesterol metabolite, is a potent liver X receptor (LXR) antagonist. Larsucosterol sodium as a potent endogenous regulator decreases lipogenesis. Larsucosterol sodium inhibits the cholesterol biosynthesis via decreasing mRNA levels and inhibiting the activation of SREBP-1 .

HY-W050031

(S)-3-Hydroxybutanoic acid 1 Publications Verification (S)-β-Hydroxybutanoic acid; L-(+)-3-Hydroxybutyric acid; L-β-Hydroxybutyric acid	Microorganisms Classification of Application Fields Ketones, Aldehydes, Acids Source classification Other Diseases Endogenous metabolite Disease Research Fields	Endogenous Metabolite
(S)-3-Hydroxybutanoic acid is a normal human metabolite, that has been found elevated in geriatric patients remitting from depression. In humans, 3-Hydroxybutyric acid is synthesized in the liver from acetyl-CoA, and can be used as an energy source by the brain when blood glucose is low.

HY-W017464

NAPQI	Structural Classification Alkaloids Classification of Application Fields Other Alkaloids Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Drug Metabolite Endogenous Metabolite
NAPQI is the toxic metabolite of Acetaminophen (HY-66005). NAPQI is also an inhibitor of enzymes in the vitamin K cycle. NAPQI is rapidly detoxified by glutathione (GSH), but in situations of GSH deficiency, excess NAPQI reacts with cysteine residues in proteins, causing cell death and toxicity in the liver .

HY-W018392

Mono-(2-ethylhexyl) phthalate Maximum Cited Publications 6 Publications Verification MEHP; Phthalic acid mono-2-ethylhexyl ester	Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite
Mono-(2-ethylhexyl) phthalate (MEHP) is a major bioactive metabolite of diethylhexyl phthalate (DEHP). Mono-(2-ethylhexyl) phthalate can promote fatty acid synthesis in hepatocytes by regulating the expression of relevant genes and proteins, contributing to non-alcoholic fatty liver disease (NAFLD) .

HY-139576B

Larsucosterol (trimethylamine) DUR-928 (trimethylamine)	Structural Classification Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields Steroids	LXR Endogenous Metabolite
Larsucosterol (DUR-928) trimethylamine, a cholesterol metabolite, is a potent liver X receptor (LXR) antagonist. Larsucosterol trimethylamine as a potent endogenous regulator decreases lipogenesis. Larsucosterol trimethylamine inhibits the cholesterol biosynthesis via decreasing mRNA levels and inhibiting the activation of SREBP-1 .

HY-113381

2-Hydroxybutyric acid α-Hydroxybutyric acid	Structural Classification Human Gut Microbiota Metabolites Microorganisms Classification of Application Fields Ketones, Aldehydes, Acids Source classification Disease markers Endocrine diseases Metabolic Disease Endogenous metabolite Disease Research Fields Cardiovascular System Disorder	Endogenous Metabolite
2-Hydroxybutyric acid (α-Hydroxybutyric acid ) is converted from 2-Aminobutyric acid, with 2-oxobutyric acid as an intermediate metabolite . 2-Hydroxybutyric acid is a potential biomarker for type 2 diabetes and preeclampsia . 2-Hydroxybutyric acid prevents the acetaminophen (AP)-induced liver injury .

HY-W040705

2-(Methylamino)benzoic acid N-Methylanthranilic acid	Structural Classification Ketones, Aldehydes, Acids Source classification Endogenous metabolite	Drug Metabolite
2-(Methylamino)benzoic acid is the main metabolite of methyl-N-methylanthranilates (MMA) (HY-76705) and is the compound in which the ester group is converted. MMA can be isolated from citrus fruits and has potential analgesic activity. 2-(Methylamino)benzoic acid was used to detect the metabolic levels of MMA in rat liver .

HY-N0904

Ginsenoside C-K 3 Publications Verification Ginsenoside compound K; Ginsenoside K	Panax ginseng C. A. Meyer Triterpenes Classification of Application Fields Terpenoids Source classification Plants Inflammation/Immunology Disease Research Fields Araliaceae	COX NO Synthase Cytochrome P450
Ginsenoside C-K, a bacterial metabolite of G-Rb1, exhibits anti-inflammatory effects by reducing iNOS and COX-2. Ginsenoside C-K exhibits an inhibition against the activity of CYP2C9 and CYP2A6 in human liver microsomes with IC₅₀s of 32.0±3.6 μM and 63.6±4.2 μM, respectively.

HY-113161

L-Octanoylcarnitine	Structural Classification Immune System Disorder Classification of Application Fields Ketones, Aldehydes, Acids Source classification Disease markers Metabolic Disease Endocrine diseases Endogenous metabolite Disease Research Fields	Endogenous Metabolite
L-Octanoylcarnitine is a plasma metabolite and a physiologically active form of octanoylcarnitine. L-Octanoylcarnitine can be used for the research of breast cancer .

HY-W354498

L-Octanoylcarnitine hydrochloride	Structural Classification Natural Products Classification of Application Fields Source classification Endogenous metabolite Disease Research Fields Cancer	Endogenous Metabolite
L-Octanoylcarnitine hydrochloride is a plasma metabolite and a physiologically active form of octanoylcarnitine. L-Octanoylcarnitine hydrochloride can be used for the research of breast cancer .

HY-N0904R

Ginsenoside C-K (Standard) Ginsenoside compound K(Standard); Ginsenoside K (Standard)	Panax ginseng C. A. Meyer Structural Classification Classification of Application Fields Terpenoids Source classification Plants Inflammation/Immunology Disease Research Fields Araliaceae	COX NO Synthase Cytochrome P450
Ginsenoside C-K (Standard) is the analytical standard of Ginsenoside C-K. This product is intended for research and analytical applications. Ginsenoside C-K, a bacterial metabolite of G-Rb1, exhibits anti-inflammatory effects by reducing iNOS and COX-2. Ginsenoside C-K exhibits an inhibition against the activity of CYP2C9 and CYP2A6 in human liver microsomes with IC₅₀s of 32.0±3.6 μM and 63.6±4.2 μM, respectively.

HY-N6792

T-2 Toxin 1 Publications Verification T-2 Mycotoxin	Structural Classification Microorganisms Classification of Application Fields Terpenoids Sesquiterpenes Source classification Metabolic Disease Disease Research Fields	Apoptosis DNA/RNA Synthesis
T-2 Toxin (T-2 Mycotoxin) is a toxic trichothecene mycotoxin produced by various Fusarium species in feedstuffs and cereal grains, LD₅₀ values of T-2 Toxin in mice and rats are 5.2 and 1.5 mg/kg BW ^a,respectively . T-2 Toxin (T-2 Mycotoxin) can be transformed into a variety of metabolite, the typical metabolites of T-2 toxin in animals are HT-2 toxin and T-2-triol, which are hydrolysates . T-2 Toxin (T-2 Mycotoxin) is an inhibitor of protein synthesis resulting from binding peptidyltransferase, which is an integral part of the 60s ribosomal subunit. T-2 Toxin (T-2 Mycotoxin) inhibits the synthesis of DNA and RNA, interferes with the metabolism of membrane phospholipids, and increases the level of liver lipid peroxides . T-2 Toxin (T-2 Mycotoxin) induces apoptosis in the immune system, gastrointestinal tissues, and fetal tissues .

Cat. No.	Product Name	Chemical Structure

HY-32349S

Ercalcidiol-d3

Ercalcidiol-d₃ is the deuterium labeled Ercalcidiol. Ercalcidiol is a metabolite of Vitamins D2. Ercalcidiol can be used as an indicator of vitamins D status .

HY-B0794S

AZ7550-d5
AZ7550-d₅ is the deuterium labeled AZ7550 (HY-B0794). AZ7550, an active metabolite of Osimtinib (AZD9291; HY-15772), inhibits the activity of IGF1R with an IC50 of 1.6 μM[1][2].

HY-129491S

O-Desmethyl Midostaurin-d5
O-Desmethyl Midostaurin-d₅ is a deuterium labeled O-Desmethyl PKC412. O-Desmethyl Midostaurin (CGP62221; O-Desmethyl PKC412) is the active metabolite of Midostaurin (HY-10230) via cytochrome P450 liver enzyme metabolism[1].

HY-121385S

Hydroxy Bosentan-d6
Hydroxy Bosentan-d₆ is deuterium labeled Hydroxy bosentan. Hydroxy bosentan (Ro 48-5033) is a primary metabolite of Bosentan (BOS) metabolized by the cytochrome P450 system in the liver. Ro 48-5033 assists BOS pharmacologically, retaining 10%-20% activities[1].

HY-121385S1

Hydroxy Bosentan-d4
Hydroxy Bosentan-d₄ is deuterium labeled Hydroxy bosentan. Hydroxy bosentan (Ro 48-5033) is a primary metabolite of Bosentan (BOS) metabolized by the cytochrome P450 system in the liver. Ro 48-5033 assists BOS pharmacologically, retaining 10%-20% activities[1].

HY-B1984S

p,p'-DDD-d8
p,p'-DDD-d₈ is the deuterium labeled p,p'-DDD[1]. p,p'-DDD is a major metabolite of p,p'-DDT. p,p'-DDD occurs in the feces and livers of rats, that are given p,p'-DDT by stomach tube, but not of rats injected intraperitoneally with p,p'-DDT[2][3].

HY-W016099S

3-Methyl-2-quinoxalinecarboxylic acid-d4
3-Methyl-2-quinoxalinecarboxylic acid-d₄ is the deuterium labeled 3-Methyl-2-quinoxalinecarboxylic acid. 3-Methyl-2-quinoxalinecarboxylic acid (MQCA), an important N-oxide reductive metabolite of Quinocetone or Olaquindox, potently inhibits the growth of Chang liver cells through S phase arrest of the cell cycle[1].

HY-113161S

L-Octanoylcarnitine-d3
L-Octanoylcarnitine-d₃ is the deuterium-labeled L-Octanoylcarnitine (HY-113161). L-Octanoylcarnitine-d₃ is a plasma metabolite and a physiologically active form of octanoylcarnitine. L-Octanoylcarnitine-d₃ can be used for the research of breast cancer .

HY-135810S

Cletoquine-d4

Cletoquine-d₄ is deuterium labeled Cletoquine. Cletoquine (Desethylhydroxychloroquine) is a major active metabolite of Hydroxychloroquine. Cletoquine is produced in the liver by CYP2D6, CYP3A4, CYP3A5, and CYP2C8 isoenzymes. Cletoquine is also a Chloroquine derivative and has the ability to against the chikungunya virus (CHIKV). Cletoquine has antimalarial effects and has the potential for autoimmune diseases treatment[1][2].

HY-135810S1

Cletoquine-d4-1

Cletoquine-d₄-1 is the deuterium labeled Cletoquine. Cletoquine (Desethylhydroxychloroquine) is a major active metabolite of Hydroxychloroquine. Cletoquine is produced in the liver by CYP2D6, CYP3A4, CYP3A5, and CYP2C8 isoenzymes. Cletoquine is also a Chloroquine derivative and has the ability to against the chikungunya virus (CHIKV). Cletoquine has antimalarial effects and has the potential for autoimmune diseases treatment[1][2].

HY-119695AS

Simvastatin acid-d6 ammonium

Simvastatin acid-d₆ (ammonium)mis the deuterium labeled Simvastatin acid ammonium. Simvastatin ammonium is an active metabolite of simvastatin lactone mediated by CYP3A4/5 in the intestinal wall and liver (pKa=5.5). Simvastatin ammonium reduces indoxyl sulfate-mediated reactive oxygen species and modulates OATP3A1 expression in cardiomyocytes and HEK293 cells transfected with the OATP3A1 gene[1].

HY-W018392S

Mono-(2-ethylhexyl) phthalate-d4

Mono-(2-ethylhexyl) phthalate-d₄ is a deuterium labeled Mono-(2-ethylhexyl) phthalate (HY-W018392). Mono-(2-ethylhexyl) phthalate (MEHP) is a major bioactive metabolite of diethylhexyl phthalate (DEHP). Mono-(2-ethylhexyl) phthalate can promote fatty acid synthesis in hepatocytes by regulating the expression of relevant genes and proteins, contributing to non-alcoholic fatty liver disease (NAFLD) .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks